These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 39273701)

  • 1. Prostate-Specific Membrane Antigen Biology and Pathophysiology in Prostate Carcinoma, an Update: Potential Implications for Targeted Imaging and Therapy.
    Maes J; Gesquière S; De Spiegeleer A; Maes A; Van de Wiele C
    Int J Mol Sci; 2024 Sep; 25(17):. PubMed ID: 39273701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and evaluation of a novel urea-based
    Zha Z; Ploessl K; Choi SR; Wu Z; Zhu L; Kung HF
    Nucl Med Biol; 2018 Apr; 59():36-47. PubMed ID: 29459281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging.
    Eder M; Schäfer M; Bauder-Wüst U; Hull WE; Wängler C; Mier W; Haberkorn U; Eisenhut M
    Bioconjug Chem; 2012 Apr; 23(4):688-97. PubMed ID: 22369515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.
    Aggarwal R; Wei X; Kim W; Small EJ; Ryan CJ; Carroll P; Cooperberg M; Evans MJ; Hope T
    Eur Urol Oncol; 2018 May; 1(1):78-82. PubMed ID: 31100231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and Evaluation of
    Zhao R; Ploessl K; Zha Z; Choi S; Alexoff D; Zhu L; Kung HF
    Mol Pharm; 2020 Dec; 17(12):4589-4602. PubMed ID: 33108189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.
    Pillai MRA; Nanabala R; Joy A; Sasikumar A; Russ Knapp FF
    Nucl Med Biol; 2016 Nov; 43(11):692-720. PubMed ID: 27589333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer.
    Kratochwil C; Afshar-Oromieh A; Kopka K; Haberkorn U; Giesel FL
    Semin Nucl Med; 2016 Sep; 46(5):405-18. PubMed ID: 27553466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer: An Update on Important Pitfalls.
    Sheikhbahaei S; Werner RA; Solnes LB; Pienta KJ; Pomper MG; Gorin MA; Rowe SP
    Semin Nucl Med; 2019 Jul; 49(4):255-270. PubMed ID: 31227049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of a Small-Molecule Drug Conjugate for Prostate Cancer Targeted Theranostics.
    Kumar A; Mastren T; Wang B; Hsieh JT; Hao G; Sun X
    Bioconjug Chem; 2016 Jul; 27(7):1681-9. PubMed ID: 27248781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors of prostate-specific membrane antigen in the diagnosis and therapy of metastatic prostate cancer - a review of patent literature.
    Ha H; Kwon H; Lim T; Jang J; Park SK; Byun Y
    Expert Opin Ther Pat; 2021 Jun; 31(6):525-547. PubMed ID: 33459068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors.
    Gourni E; Canovas C; Goncalves V; Denat F; Meyer PT; Maecke HR
    PLoS One; 2015; 10(12):e0145755. PubMed ID: 26700033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current use of PSMA-PET in prostate cancer management.
    Maurer T; Eiber M; Schwaiger M; Gschwend JE
    Nat Rev Urol; 2016 Apr; 13(4):226-35. PubMed ID: 26902337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [
    Clore J; Scott PJH
    Expert Rev Mol Diagn; 2024 Jul; 24(7):565-582. PubMed ID: 39054633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PSMA-11-Derived Dual-Labeled PSMA Inhibitors for Preoperative PET Imaging and Precise Fluorescence-Guided Surgery of Prostate Cancer.
    Baranski AC; Schäfer M; Bauder-Wüst U; Roscher M; Schmidt J; Stenau E; Simpfendörfer T; Teber D; Maier-Hein L; Hadaschik B; Haberkorn U; Eder M; Kopka K
    J Nucl Med; 2018 Apr; 59(4):639-645. PubMed ID: 29191856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel [
    Wang R; Jin W; Luo Y; Hong H; Zhao R; Li L; Yan L; Qiao J; Ploessl K; Zhu L; Kung HF
    Mol Pharm; 2024 Jul; 21(7):3256-3267. PubMed ID: 38856975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of a [Al
    Al-Momani E; Israel I; Samnick S
    Appl Radiat Isot; 2017 Dec; 130():102-108. PubMed ID: 28950199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of
    Hofman MS; Eu P; Jackson P; Hong E; Binns D; Iravani A; Murphy D; Mitchell C; Siva S; Hicks RJ; Young JD; Blower PJ; Mullen GE
    J Nucl Med; 2018 Apr; 59(4):625-631. PubMed ID: 28986512
    [No Abstract]   [Full Text] [Related]  

  • 18.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and pre-clinical evaluation of a new class of high-affinity
    Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and preclinical evaluation of an Al
    Boschi S; Lee JT; Beykan S; Slavik R; Wei L; Spick C; Eberlein U; Buck AK; Lodi F; Cicoria G; Czernin J; Lassmann M; Fanti S; Herrmann K
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2122-2130. PubMed ID: 27329046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.